Condition: Non Small Cell Lung Cancer · Metastatic · Recurrent · Sponsor: Memorial Sloan Kettering Cancer Center
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
This description comes directly from the study's public registry record.
Gregory Riely, MD, PhD · 646-608-3913 · rielyg@mskcc.org
Alexander Drilon, MD · 646-608-3758
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering West Harrison (All Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (All Protocol Activities) | Rockville Centre, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06007937